A first malaria vaccine would be used in addition to existing malaria control tools.

The global malaria vaccine community has provided guidance for developing malaria vaccines. Last updated in 2013, the Malaria Vaccine Technology Roadmap provides interim and long-term goals for vaccines to help control and eliminate malaria. The interim goal for 2015 was to develop and license a first-generation malaria vaccine that has protective efficacy of more than 50 percent against severe disease and death, with protection lasting longer than one year.

Given the modest efficacy expected, a first-generation malaria vaccine is intended to complement existing methods that countries use to prevent, diagnose, and treat malaria.  

RTS,S/AS01 (trade name Mosquirix™) is the candidate vaccine furthest along in development globally, the outcome of a long-standing collaboration between PATH and GSK that began in 2001. In January 2016, the World Health Organization (WHO) published its position paper on RTS,S, recommending pilot implementation of the vaccine in African settings of moderate-to-high parasite transmission. RTS,S is the first malaria vaccine to receive a WHO recommendation, and the first to receive a positive opinion from a stringent regulatory authority, the European Medicines Agency (EMA).